Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (0)

Galvus (vildagliptin) is “not inferior to” Avandia (rosiglitazone) in Treating Type 2 Diabetes


Mar 16, 2007

A 24-week study compared the effectiveness and safety of Galvus (vildagliptin), a DPP-4 inhibitor, with Avandia (rosiglitazone), a thiazolidinedione, in a double-blind, randomized, controlled, multi-center study. Both drugs had similar effects on A1c’s: Galvus reduced A1c by 1.1 %, and Avandia reduced A1c by 1. 3%. Most notably, patients did not gain weight with Galvus, but gained an average of 3.4 pounds with Avandia.

Galvus, made by Novartis, is in the same class as sitagliptin (Januvia), another DPP-4 inhibitor. Unlike Januvia, Galvus has not been approved by the FDA. FDA approval was expected by November 2006, but then the FDA asked for more data about studies linking Galvus to skin lesions in monkeys. In late February 2007, the FDA asked for a clinical study in patients with kidney impairment. It now looks as if Galvus will not be approved by the FDA for a year or more.

Sources: Diabetes Care
Associated Press
Forbes.com


Categories: A1c Test, Diabetes, Diabetes, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Click Here To View Or Post Comments

Mar 16, 2007

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.